CFO transition
Yarrow Bioscience, Inc. CFO transition: Tyler Zeronda to succeed Mutya Harsch
Yarrow Bioscience, Inc. reported in a Form 8-K filed July 28, 2026 that Tyler Zeronda will succeed Mutya Harsch as Chief Financial Officer, effective July 27, 2026.
In the filing's words
On July 27, 2026, the Board appointed Rebecca Frey, Pharm.D. as the Company’s Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Yarrow Bioscience, Inc. (VYNE) |
|---|---|
| Event | Transition |
| Incoming | Tyler Zeronda |
| Outgoing | Mutya Harsch |
| Title in the filing | Chief Financial Officer |
| Effective | July 27, 2026 |
| 8-K filed | July 28, 2026 |
| Internal promotion | No |
| Prior role (per filing) | Chief Financial Officer and Treasurer, VYNE Therapeutics Inc. (Nasdaq: VYNE) |
| SEC CIK | 0001566044 |
Yarrow Bioscience, Inc. reported this change in a Form 8-K, Item 5.02, filed July 28, 2026. The filing's own words are quoted above.
Same industry, July 2026
7Other moves filed that month at companies the roster files under SIC “Pharmaceutical Preparations”.
3 months ago· 2026-07-31AppointmentGCAN
The Greater Cannabis Company, Inc. appoints Michelle Cervantes Vivanco as CFO
3 months ago· 2026-07-22InterimKROS
Keros Therapeutics, Inc. names Annita Tanini interim CFO
3 months ago· 2026-07-20AppointmentPMHS
Polomar Health Services, Inc. appoints Douglas Beck as CFO
4 months ago· 2026-07-13AppointmentMBX
MBX Biosciences, Inc. appoints John Smither as CFO
4 months ago· 2026-07-08TransitionOVID
Ovid Therapeutics Inc. CFO transition: Charles Carter to succeed Jeffrey Rona
4 months ago· 2026-07-06TransitionLGVN
Longeveron Inc. CFO transition: Marie Washburn to succeed Lisa Locklear
4 months ago· 2026-07-06AppointmentOGEN
Oragenics, Inc. appoints John Spencer as CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Tyler Zeronda? Send a correction with the primary source.